Modified Vaccinia Virus Vectored Vaccine Development Services for SARS-CoV-2

The emergence and re-emergence of pathogens is a global challenge to public health. The novel coronavirus (SARS-CoV-2) that broke out in Wuhan, China in December 2019 has now spread to many countries around the world, triggering more containment efforts. Therefore, the development of a vaccine against SARS-CoV-2 is imminent. Based on our knowledge of coronavirus and the use of advanced vaccine development platform technology, Creative Biolabs has proposed the SARS-CoV-2 vaccine development service with vaccinia virus as the vector.

Introduction of Modified Vaccinia Virus

Genetically modified viruses (GMVs) or viral vectors of homologous or heterologous disease antigens are considered to be very suitable for treating difficult-to-treat diseases or the absence of effective conventional vaccines, such as acquired immune deficiency syndrome (AIDS) and malaria. Some of the advantages of GMVs in vaccination are that they enhance immunogenicity without the need for adjuvants and induce a strong cytotoxic T lymphocyte response to eliminate virus-infected cells. Many viruses have been used as GMVs for vaccination purposes, and the Vaccinia virus (VACV) is one of them. Due to the application of VACV and modified vaccinia virus Ankara (MVA) in smallpox vaccination, VACV vectors have good historical safety advantages. Therefore, MVA is the preferred carrier for human applications because of its strong security and immunogenicity in vivo.

MVA Vectored Vaccine Development Services for SARS-CoV-2

Coronavirus-induced SARS (severe acute respiratory syndrome) and MERS (Middle East respiratory syndrome) originate from zoonotic diseases and are sometimes associated with fatal diseases. Recombinant MVA, which was rapidly applied in response to the emergence of SARS-CoV or MERS-CoV, proved that the vector system is suitable to deal with the potential threat of sudden infectious diseases.

Based on previous knowledge and project accumulation, we propose a vaccine development service that uses MVA as a vector to deliver heterologous antigen, SARS-CoV-2. Theoretically, this vaccine can transcribe the target gene sequence only under the highly specific control of the poxvirus promoter recognized and activated by virus-encoded enzymes and transcription factors. Recombinant genes are transiently expressed only after infection with non-replicating MVA. Because host cells are not infected with MVA survive, complete elimination of recombinant virus and recombinant DNA can occur within days of vaccination, ensuring the safety of the vaccine.

The prevalence and widespread distribution of coronaviruses, the extensive genetic diversity and frequent recombination of their genomes, and the increased interfacial activity between humans and animals have led to strong attention to their infections. For the outbreak of SARS-CoV-2, experts at Creative Biolabs quickly responded and provided the MVA vectored vaccine development services for SARS-CoV-2. For safety reasons, the benefits of using MVA as a live virus-based vaccine vector are based on the ability to elicit the specific secondary immune response after repeated vaccination. If you are interested in our services, please contact us.

For Research Use Only. We do not provide direct services or products for patients.